Ferring reports positive safety data from Firmagon study

Ferring has reported results from a pooled analysis of six prospective randomised drug trials that help to demonstrate the strong safety performance of its prostate cancer drug Firmagon.

According to data from the study, Ferring's gonadotropin releasing hormone antagonist was associated with a lower risk of cardiovascular events or deaths compared to commonly prescribed luteinising hormone-releasing hormone (LHRH) agonists.

Moreover, Firmagon patients experienced significantly higher overall survival rates and improved disease control, as demonstrated by a decrease in fractures and a lower incidence of renal or urinary tract adverse events.

This makes the drug a useful treatment option for prostate cancer, which is the most common form of male cancer in the western world.

Professor Kurt Miller from Charite-Universitatsmedizin in Berlin said these positive findings "should be taken into consideration when considering treatment options for patients".

This comes after Ferring also reported positive data on its ulcerative colitis treatment Pentasa last month.